Download
12992_2024_Article_1019.pdf 1,02MB
WeightNameValue
1000 Titel
  • Pull me – push you? The disparate financing mechanisms of drug research in global health
1000 Autor/in
  1. Matthey, Max Alexander |
  2. Hollis, Aidan |
1000 Verlag BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-02-19
1000 Erschienen in
1000 Quellenangabe
  • 20(1):14
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12992-024-01019-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877918/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>There is an inconsistency in the way pharmaceutical research is financed. While pull mechanisms are predominantly used to incentivize later-stage pharmaceutical research for products with demand in the Global North, so-called neglected diseases are chiefly financed by push funding. This discrepancy has so far been ignored in the academic debate, and any compelling explanation for why we draw the line between push and pull at poor people is lacking.</jats:p> </jats:sec><jats:sec> <jats:title>Main body</jats:title> <jats:p>Clinical development of new pharmaceuticals is chiefly financed by free market pull mechanisms. Even in cases where markets fail to deliver adequate incentives, demand enhancement mechanisms are used to replicate pull funding artificially, for example, with subscription models for antibiotics. Push funding in clinical research is almost always used when the poverty of patients means that markets fail to create sufficient demand. The general question of whether push or pull generally is the more efficient way to conduct pharmaceutical research arises.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>If the state is efficient in directing limited budgets for pharmaceutical research, push funding should be expanded to global diseases. If private industry is the more efficient actor, there would be enormous value in experimenting more aggressively with different approaches to enhance market demand artificially for neglected diseases.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Pharmaceutical research
lokal Anti-Bacterial Agents [MeSH]
lokal Humans [MeSH]
lokal Neglected Diseases/drug therapy [MeSH]
lokal Pharmaceutical Research [MeSH]
lokal Neglected diseases
lokal Pull mechanisms
lokal Global Health [MeSH]
lokal Policy making
lokal Debate
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0009-0005-4988-8252|https://frl.publisso.de/adhoc/uri/SG9sbGlzLCBBaWRhbg==
1000 Hinweis
  • DeepGreen-ID: 9bbbe0ff637042e8aaf816dc811df7b2 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Canadian Institutes of Health Research |
  2. Private Universität Witten/Herdecke gGmbH |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Canadian Institutes of Health Research |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Private Universität Witten/Herdecke gGmbH |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6493662.rdf
1000 Erstellt am 2025-02-03T21:28:22.336+0100
1000 Erstellt von 322
1000 beschreibt frl:6493662
1000 Zuletzt bearbeitet 2025-09-12T15:40:07.357+0200
1000 Objekt bearb. Fri Sep 12 15:40:07 CEST 2025
1000 Vgl. frl:6493662
1000 Oai Id
  1. oai:frl.publisso.de:frl:6493662 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source